A phase 3 randomized placebo-controlled trial of tadalafil for Duchenne muscular dystrophy

OBJECTIVE: To conduct a randomized trial to test the primary hypothesis that once-daily tadalafil, administered orally for 48 weeks, lessens the decline in ambulatory ability in boys with Duchenne muscular dystrophy (DMD). METHODS: Three hundred thirty-one participants with DMD 7 to 14 years of age...

Descripción completa

Detalles Bibliográficos
Autores principales: Victor, Ronald G., Sweeney, H. Lee, Finkel, Richard, McDonald, Craig M., Byrne, Barry, Eagle, Michelle, Goemans, Nathalie, Vandenborne, Krista, Dubrovsky, Alberto L., Topaloglu, Haluk, Miceli, M. Carrie, Furlong, Pat, Landry, John, Elashoff, Robert, Cox, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5664308/
https://www.ncbi.nlm.nih.gov/pubmed/28972192
http://dx.doi.org/10.1212/WNL.0000000000004570

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5664308/
https://www.ncbi.nlm.nih.gov/pubmed/28972192
http://dx.doi.org/10.1212/WNL.0000000000004570

Ejemplares similares